CNO Financial Group, Inc. (CNO) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A indicate strong financial performance, with growth across divisions, solid investment income, and a positive outlook on direct-to-consumer sales. While there were no specific new partnership announcements, the reaffirmation of 2025 guidance and stable financial health are positives. The Q&A addressed potential concerns, showing confidence in sustaining growth and managing competition. The market cap suggests moderate sensitivity, leading to a positive short-term stock price reaction.
Key Financial Performance
Total new annualized premiums $120 million, up 17% year-over-year. Reasons for the increase include double-digit insurance sales growth in both divisions and multiple product line sales records.
Operating earnings per diluted share $0.87. Earnings benefited from favorable insurance product margin and solid investment results, reflecting growth in the business and expansion of the portfolio book yield.
Book value per diluted share (excluding AOCI) $38.05, up 6% year-over-year. This reflects consistent growth in the business and favorable market conditions.
Annuity collected premiums Surpassed $500 million for the first time in a single quarter, driven by 19% growth. Reasons include steady execution and focus on the underserved middle-income market.
In-force annuity account values Up 8% year-over-year. This growth is attributed to the stability provided by captive distribution and long-term relationships with agents.
Client assets in brokerage and advisory $4.6 million, up 27% year-over-year. Reasons include a 13% increase in new accounts and a 12% increase in average account size.
Total life insurance Up 20% year-over-year. Record direct-to-consumer life insurance sales were up 29%, and field agent-sold life insurance was up 4%. Growth was driven by a rebound in D2C lead volumes and diversification into digital and web channels.
Supplemental health Up 21% year-over-year. Growth reflects strong customer demand for solutions to cover out-of-pocket gaps in medical coverage.
Medicare Supplement Up 18% year-over-year. Growth is attributed to steady demand for Medicare products and the ability to offer more coverage options.
Producing agent count Up 3% year-over-year, marking the 10th consecutive quarter of growth. Growth is driven by investments in technology and operational efficiency.
Worksite life and health NAP Up 16% year-over-year. Growth is attributed to strategic growth initiatives, geographic expansion, and increased agent productivity.
Net investment income Up 2% year-over-year. Growth is driven by an 11 basis point increase in average yield on allocated investments and a 7% increase in net investment income allocated to products.
Market value of invested assets Grew 5% year-over-year. Growth is driven by business growth and market appreciation on the investment portfolio.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New annualized premiums: Record total new annualized premiums of $120 million, up 17%.
Annuity collected premiums: Surpassed $500 million for the first time in a single quarter, driven by 19% growth.
Brokerage and advisory growth: Client assets in brokerage and advisory were up 27% to $4.6 million, a new record.
Life and health NAP: Posted double-digit growth, up 17%.
Direct-to-consumer life insurance sales: Up 29%, with web and digital sales accounting for over 30% of D2C leads, up 39% year-over-year.
Supplemental health and Medicare Supplement: Supplemental health was up 21%, and Medicare Supplement was up 18%.
Geographic expansion in Worksite division: Contributed 25% of NAP growth, marking the sixth consecutive quarter of growth from this program.
New group clients in Worksite division: NAP from new group clients was up 84%.
Agent productivity and retention: Producing agent count was up 3%, marking the 10th consecutive quarter of growth. Registered agent count increased by 6%.
Accelerated underwriting: Delivered an 89% instant decision rate on submitted policies, up 12% over Q1 2025.
New CRM platform in Worksite division: Launched to enable sales and new group development, enhancing agent productivity.
Optavise Clear product: Introduced as a unified package for employees, adding new Medicare advocacy services and enhancing user technology.
Marketing campaign: Launched 'Health is Human' campaign to highlight the value of human interaction coupled with technology.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Economic Uncertainty and Market Volatility: The CEO highlighted the importance of personal interaction by agents during times of economic uncertainty and market volatility, indicating potential challenges in maintaining customer trust and sales momentum in such conditions.
Medicare Supplement Claims: Higher claims in Medicare Supplement products were noted, though the company has the ability to adjust rates annually to address this issue.
Alternative Investment Yields: The yield on alternative investments remains below the long-term run rate expectation, which could impact overall investment income.
Medicare Advantage Sales: Medicare Advantage policies sold were down for the quarter, though up for the year, indicating potential challenges in maintaining consistent growth in this segment.
Regulatory Approvals for Bermuda Transactions: The company is working with domestic regulators and the Bermuda Monetary Authority to explore additional transactions, which could face regulatory hurdles.
Expense Management: The company adjusted its expense ratio guidance slightly downward, reflecting better operating leverage, but this indicates ongoing pressure to manage expenses effectively.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue and Sales Growth: CNO Financial Group expects continued growth in revenue and sales, driven by strong performance in both Consumer and Worksite divisions. The company anticipates sustained double-digit growth in insurance sales across multiple product lines, including life and health insurance, as well as annuities.
Return on Equity (ROE): The company is on track to achieve an operating return on equity of around 10.5% for the full year 2025 and aims for a 3-year target of 11.5% by 2027, reflecting a 150 basis point improvement from 2024.
Annuity and Brokerage Growth: CNO projects continued growth in annuity collected premiums, which surpassed $500 million in Q2 2025, marking the eighth consecutive quarter of growth. Brokerage and advisory assets are also expected to grow, with client assets up 27% year-over-year.
Medicare and Health Products: The company foresees steady demand for Medicare products, driven by demographic trends, with more than 11,000 people in the U.S. turning 65 daily. Growth in supplemental health and Medicare Supplement products is expected to continue.
Expense Ratio: CNO has adjusted its expense ratio guidance, lowering the upper bound to 19.2% from 19.4%, reflecting better operating leverage as the business grows.
Capital Deployment: The company plans to continue returning capital to shareholders through share repurchases, with a focus on maintaining target risk-based capital and Holdco liquidity levels.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividends returned to shareholders: $117 million in the quarter and $234 million year-to-date.
Share repurchases: $100 million of excess capital deployed on share repurchases in the quarter, contributing to an 8% reduction in weighted average diluted shares outstanding.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide more details on the momentum from web digital sales and its sustainability?
A:Gary Bhojwani explained that the direct-to-consumer business is growing well, with web and digital sales up 39% year-over-year, representing nearly 1/3 of total D2C sales. He expects this momentum to continue over the long term, though not every quarter will see such high growth.
Q:Can you discuss the differences in your Medicare Supplement business compared to other Medicare areas?
A:Gary Bhojwani highlighted three key differences: distribution profile (captive agents with better persistency), underwriting risk (Medicare Supplement funded by policyholder premiums with annual repricing), and regulatory risk (focused on Medicare Advantage, which CNO only distributes, not manufactures).
Q:Can you elaborate on the expense experience in the quarter and the change in guidance?
A:Paul McDonough stated that expenses were in line with expectations, with a better expense ratio due to improved operating leverage as the business grows.
Q:What are the trends in long-term care utilization claim patterns?
A:Paul McDonough noted a continuation of favorable claims experience but expects claims to trend closer to pre-COVID levels in the long term.
Q:Can you share details on repricing of Medicare Supplement products and its impact on margins?
A:Paul McDonough mentioned a modest increase in claims experience, with rate filings averaging around 10%, effective in Q1 of next year.
Q:Have you observed changes in competition in the fixed annuity space?
A:Gary Bhojwani acknowledged intense competition, especially from asset managers targeting high-net-worth clients. However, CNO focuses on middle-income clients with less competition in that segment.
Q:How diversified is your mix of Medicare Advantage carriers, and is there any risk from carrier payment issues?
A:Gary Bhojwani stated that CNO works with about 20 carriers, with no concentration risk. He emphasized no risk to CNO from carrier payment issues.
Q:Was there anything unusual in the $520 million annuity sales, and what are the trends in spreads?
A:Gary Bhojwani noted no unusual factors in the sales, which are expected to remain strong. Paul McDonough added that spreads were stable sequentially and year-over-year.
Q:Does the Fed cutting rates impact the annuity business?
A:Paul McDonough explained that rate changes influence product par rates but are not expected to materially affect demand.
Q:Can you provide more details on direct-to-consumer sales outside of web and digital?
A:Gary Bhojwani mentioned strong production from direct sales and independent third-party partnerships, in addition to web and digital.
Q:What is the status of statutory income or RBC in the quarter?
A:Paul McDonough explained that statutory income was slightly below expectations due to alternative investments, but RBC remained stable at 378%, above the 375% target.
Q:What are the current investment opportunities and changes in the environment?
A:Eric Johnson highlighted opportunities in residential mortgage loans, CRE CDOs, and taxable munis, with steady progress in book yield and core income.
Q:What is the status of recruiting activity and its impact on sales?
A:Gary Bhojwani reported strong recruiting and productivity, with no expected slowdown in sales.
Q:Does lower statutory earnings affect free cash flow generation guidance?
A:Paul McDonough stated that free cash flow was below expectations in the first half due to tax timing but remains confident in the full-year guidance of $200-$250 million.
Q:What is the progress with the Bermuda company and its potential impact on ROE?
A:Gary Bhojwani expressed satisfaction with the Bermuda operation's development and ongoing discussions with regulators, but refrained from providing further details.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the Bermuda company's regulatory discussions and potential impacts, citing ongoing interactions with the Bermuda Monetary Authority.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Auvil
Consumer division
DC lead
Holdco liquidity
Inc Research
Joel
LLC
Optavise Clear
Research Division
Worksite division
Worksite life
account size
adjustment
book yield
campaign
claim experience
client Worksite
customer
date
digit
equity improvement
health NAP
interaction
life health
life insurance
life product
line expectation
mortality
option
party
portfolio quality
product health
productivity
repurchase risk
sale Worksite
share repurchase
spread
surrender
track return
CNO Transcript
CNO Financial Group, Inc. (CNO) Q1 2026 Earnings Call Transcript
Positive5-1
The earnings call indicates strong financial performance with significant growth in key insurance segments, robust ROE, and disciplined capital management. The Q&A reveals management's confidence in sustaining growth and improving ROE, despite some market uncertainties. The company's strategic focus on demographic trends and business growth supports a positive outlook. However, the lack of precise guidance on future ROE improvements and mortality trends adds some uncertainty. Given the company's market cap, the stock is likely to experience a positive movement of 2% to 8% over the next two weeks.
CNO Financial Group, Inc. (CNO) Q4 2025 Earnings Call Transcript
Positive2-6
The earnings call reflects a positive outlook with strong financial performance, improved ROE targets, and increased shareholder returns. Despite some challenges in discretionary purchases and Medicare Advantage, the company expects growth in Medicare Supplement sales, aligning with demographic trends. The Q&A session revealed confidence in hitting targets and maintaining regulatory relationships, although there were some vague responses. The market cap suggests moderate sensitivity to positive news, leading to an expected stock price increase of 2% to 8% over the next two weeks.
CNO Financial Group, Inc. (CNO) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call summary and Q&A reveal a positive outlook with strong revenue growth across multiple product lines, improved expense ratio guidance, and strategic capital deployment. Despite some unclear management responses, the strong D2C sales and partnerships, along with optimistic guidance, outweigh the concerns. The company's focus on shareholder returns through share repurchases and investments in growth is likely to drive a positive stock price movement. Given the market cap of $2.98 billion, a positive reaction of 2% to 8% is anticipated over the next two weeks.
CNO Financial Group, Inc. (CNO) Q2 2025 Earnings Call Transcript
Positive7-29
The earnings call summary and Q&A indicate strong financial performance, with growth across divisions, solid investment income, and a positive outlook on direct-to-consumer sales. While there were no specific new partnership announcements, the reaffirmation of 2025 guidance and stable financial health are positives. The Q&A addressed potential concerns, showing confidence in sustaining growth and managing competition. The market cap suggests moderate sensitivity, leading to a positive short-term stock price reaction.
CNO Slides
CNO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
